Sample Analysis Tables

NOFO Outcome Tables
1. Table 1 Short-term outcome: Increased access to harm reduction services and supplies
2. Table 2 Short-term outcome: Increased HCV, HIV, and HBV testing among SSP Participants
3. Table 3 Short-term outcome: Increased prevention and treatment of infections associated with
injection drug use
4. Table 4 Intermediate outcomes: Increased use of harm reduction services by PWID, Decreased
incidence of unsafe injection practices, Increased hepatitis C viral clearance among SSP participants
with hepatitis C
1. Short-term outcome: Increased access to harm reduction services and supplies (N=62)
Total Count Across all Funded SSPs: n (%)
SSP Location
Number of SSPs in the Midwest
Number of SSPs in the Northeast
Number of SSPs in the South
Number of SSPs in the West
SSP Service Delivery Model (# of SSPs for each)
Brick and mortar fixed site (including drop-in
centers)
Backpack/outreach or foot/pedestrian-based
Pop-up sites (tables, tent, etc.)
Delivery to regular locations (e.g., established
route)
Delivery to participant requested locations (e.g.,
home delivery)
Mail-based distribution
Vending machine
SSP Syringe Distribution Policies (# of SSPs for each)
One-for-one exchange (1:1)
One-for-one (1:1) plus (i.e., "rounding up" 1:1)
One-for-one exchange (1:1) with starter packs
One-for-one (1:1) plus with starter packs
Need-based
SSP Serving Specific Demographics of Participants
(# of SSPs for each)
Lesbian, gay, bisexual, or queer persons
Transgender, genderqueer, or non-binary persons
Women
American Indian or Alaska Native persons
Asian persons
Black or African-American persons
Hispanic or Latinx persons
Native Hawaiian or Other Pacific Islander persons
Persons aged < 20 years
Persons aged 20 to 29 years
Persons aged 30 to 39 years
1

Persons aged 40 to 59 years
Persons aged < or = 60 years
Persons who trade sex
2. Short-term outcome: Increased HCV, HIV, and HBV testing among SSP Participants (N=62)
Total Count Across all Funded SSPs: n (%)
Number of SSP participants screened for hepatitis C
Number of SSP participants screened for hepatitis B
Number of SSP participants screened for HIV
3. Short-term outcome: Increased prevention and treatment of infections associated with injection drug
use (N=62)
Total Count Across all Funded SSPs: n (%)
SSP participants with hepatitis C
Number of participants referred for hepatitis C
treatment
Number of participants provided onsite hepatitis C
treatment
SSP participants with HIV
Number of participants referred for antiretroviral
therapy
Number of participants provided onsite
antiretroviral therapy
SSP participants who are HIV negative
Number of participants referred for PrEP
Number of participants provided onsite PrEP
Number of SSP participants receiving hepatitis A
vaccination
Number of SSP participants receiving hepatitis B
vaccination

4. Intermediate outcomes (N=62)
Total Count Across all Funded SSPs: n (%)
Increased use of harm reduction services by PWID
Number of participant visits
Decreased incidence of unsafe injection practices
Number of syringes distributed
Increased hepatitis C viral clearance among SSP
participants with hepatitis C
Number of SSP participants attaining sustained viral
clearance of hepatitis C

2